This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PolyMedix Defensin-Mimetic Antibiotic PMX-30063 Active Against NDM-1 Drug-Resistant Bacteria

PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity in an in vitro laboratory test against the NDM-1 drug resistant strain of Klebsiella pneumonia. NDM-1 (New Delhi metallo-beta-lactamase-1) is an enzyme carried by some bacteria that are resistant to many antibiotics, including carbapenems. PMX-30063 is currently being studied in a Phase 2 clinical trial in patients for treatment of Acute Bacterial Skin and Skin Structure Infections caused by Staph bacteria.

“NDM-1 resistant bacteria are an emerging infectious threat of growing concern to the medical community,” commented Nicholas Landekic, President & CEO of PolyMedix. “We believe PMX-30063, with its unique mechanism of action that makes the development of resistance unlikely, has the potential to represent a novel approach to address this mounting problem.”

These data were presented in March 2011 to the medical community at the SuperBugs SuperDrugs conference in London by Dr. Richard Scott, Vice President of Research at PolyMedix. At the same conference, Dr. Scott also presented results with PolyMedix’s defensin-mimetic antimicrobial compounds related to additional indications, including activity against Candida albicans for oral candidiasis. These results, along with data showing anti-inflammatory properties of PolyMedix’s defensin-mimetic compounds, were published in a recent issue of Molecular Oral Microbiology. These anti-inflammatory properties may be important and beneficial in the treatment of a variety of infectious disorders, and appear to be a distinct characteristic not seen in many other antibiotic agents.

“We are very excited by the breadth and scope of our defensin-mimetic antibiotic compounds,” commented Dr. Scott. “We continue to demonstrate expanded spectrums of activities, most recently against anthrax and NDM-1 drug resistant strains. In addition, our demonstration of inherent anti-inflammatory activity is potentially an important distinction versus other antibiotics. We remain dedicated to exploring the potential for our compounds to address a number of increasingly troubling infectious diseases, including fungal infections, malaria, tuberculosis, and food borne pathogens.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs